Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Maraninchi

Showing results (11-20 of 264) with videos related to

Pageof 27
Sort By:
Bulletin Du Cancer|January 1, 1995
[Dose intensity in anticancer chemotherapy. Paris, 19 December 1994]J P Droz, D Maraninchi
Bulletin Du Cancer|January 1, 1995
[Experience with other tumors: breast, ovary, brain tumors and sarcomas]D Maraninchi, J P Droz
Bulletin Du Cancer|July 1, 1995
[Methodology and legitimacy of French clinical trials in primary chemoprevention of cancers. The point of view of the National Federation of French cancer centers]F Eisinger, D Maraninchi, T Philip
Acta Haematologica|January 1, 1985
Increased prostaglandin E production in malignant lymphomasG Sébahoun, D Maraninchi, Y Carcassonne
Lancet (London, England)|January 2, 1993
Long-term follow-up of T-cell depletion for bone marrow transplantationD Blaise, G Gravis, D Maraninchi
Nouvelle Revue Francaise D'Hematologie|January 1, 1980
Granulocytic progenitor cells (CFC) in a child with infantile genetic agranulocytosis (IGA) and in phenotypically normal parentsC Parmentier, D Maraninchi, F Teillet
La Revue Du Praticien|April 11, 1981
[Vaquez' disease: diagnostic orientation]G Sébahoun, D Maraninchi, Y Carcassonne
Presse Medicale (Paris, France : 1983)|October 26, 1988
[Ceftazidime after bone marrow graft. Current aspects]D Blaise, D Maraninchi, A M Stoppa
Journal of Hematotherapy|November 22, 1997
Will CD34+ standardization solve all problems related to cell therapy?C Chabannon, J P Moatti, D Maraninchi
La Revue Du Praticien|March 1, 1993
[Cytokines and malignant hemopathies: leukemias and bone marrow graft]D Blaise, A M Stoppa, D Maraninchi
Pageof 27

Showing results (11-20 of 264) with videos related to

Sort By:
Pageof 27
Bulletin Du Cancer|January 1, 1995
[Dose intensity in anticancer chemotherapy. Paris, 19 December 1994]J P Droz, D Maraninchi
Bulletin Du Cancer|January 1, 1995
[Experience with other tumors: breast, ovary, brain tumors and sarcomas]D Maraninchi, J P Droz
Bulletin Du Cancer|July 1, 1995
[Methodology and legitimacy of French clinical trials in primary chemoprevention of cancers. The point of view of the National Federation of French cancer centers]F Eisinger, D Maraninchi, T Philip
Acta Haematologica|January 1, 1985
Increased prostaglandin E production in malignant lymphomasG Sébahoun, D Maraninchi, Y Carcassonne
Lancet (London, England)|January 2, 1993
Long-term follow-up of T-cell depletion for bone marrow transplantationD Blaise, G Gravis, D Maraninchi
Nouvelle Revue Francaise D'Hematologie|January 1, 1980
Granulocytic progenitor cells (CFC) in a child with infantile genetic agranulocytosis (IGA) and in phenotypically normal parentsC Parmentier, D Maraninchi, F Teillet
La Revue Du Praticien|April 11, 1981
[Vaquez' disease: diagnostic orientation]G Sébahoun, D Maraninchi, Y Carcassonne
Presse Medicale (Paris, France : 1983)|October 26, 1988
[Ceftazidime after bone marrow graft. Current aspects]D Blaise, D Maraninchi, A M Stoppa
Journal of Hematotherapy|November 22, 1997
Will CD34+ standardization solve all problems related to cell therapy?C Chabannon, J P Moatti, D Maraninchi
La Revue Du Praticien|March 1, 1993
[Cytokines and malignant hemopathies: leukemias and bone marrow graft]D Blaise, A M Stoppa, D Maraninchi
Pageof 27